Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

European Patent Office Decision on Dasatinib

The European Patent Office upheld a decision that found the patent to be invalid
14 Feb 2017
Haematologic malignancies;  Anticancer agents & Biologic therapy

On 1 February 2017, Bristol-Myers Squibb (BMS) Company announced that the European Patent Office (EPO) upheld a decision with regard to European Patent No. 1169038 (the '038 patent), the Composition of Matter patent covering dasatinib, the active ingredient in Sprycel. The EPO upheld a decision that found the patent to be invalid.

This decision does not impact the patents outside of the EU.

In their announcement, the company wrote that BMS has a long-standing heritage in oncology. Sprycel will continue to be a significant asset in their broad oncology portfolio and an important treatment option for patients living with chronic myeloid leukaemia (CML). The US Food and Drug Administration (FDA) indications for dasatinib in adults are:

  • Newly diagnosed patients with Philadelphia chromosome-positive (Ph+) CML in chronic phase.
  • Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.
  • Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) with resistance or intolerance to prior therapy.
Last update: 14 Feb 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.